# Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus

> **NCT01584843** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 41 (actual)

## Conditions studied

- Strabismus

## Interventions

- **DRUG:** GSK1358820

## Key facts

- **NCT ID:** NCT01584843
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-07
- **Final completion:** 2014-06
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2015-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01584843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01584843, "Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01584843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*